Lilly's triple agonist, retatrutide, drove substantial improvements in weight, A1C, knee osteoarthritis pain, and obstructive sleep apnea, demonstrating its remarkable potential to treat obesity and i
Eli Lilly's Phase 3 clinical trials for the drug retatrutide show significant results in treating obesity, type 2 diabetes, knee osteoarthritis, and sleep apnea. The findings suggest the triple hormone receptor agonist could be a breakthrough in managing obesity-related comorbidities.
Why it matters
These results highlight a potential paradigm shift in treating obesity not just as a weight issue, but as a root cause for multiple chronic health conditions.
In TRIUMPH-1, participants on retatrutide 12 mg lost an average of 70.3 lbs (28.3%) over 80 weeks, with 65.3% achieving a BMI below 30, no longer meeting the BMI criteria for obesity
The report is based on clinical trial data and scientific presentations, maintaining a neutral, informative tone.
Get smarter about the news
Sign up free for a feed built around what you actually care about, Dive Deeper research on any story, and the full text of every article.
Create free accountAlready have an account? Sign in